Spinal and bulbar muscular atrophy (SBMA), an adult-onset neurodegenerative disease that affects males, results from a CAG triplet repeat/polyglutamine expansions in the androgen receptor (AR) gene. Patients develop progressive muscular weakness and atrophy, and no effective therapy is currently available. The tissue-specific pathogenesis, especially relative pathological contributions between degenerative motor neurons and muscles, remains inconclusive. Though peripheral pathology in skeletal muscle caused by toxic AR protein has been recently reported to play a pivotal role in the pathogenesis of SBMA using mouse models, the role of motor neuron degeneration in SBMA has not been rigorously investigated. Here we exploited synthetic antisense oligonucleotides to inhibit the RNA levels of mutant AR in the central nervous system (CNS) and explore its therapeutic effects in our SBMA by guest on
Introduction
SBMA is a late-onset neurodegenerative disorder which is characterized by progressive motor neuron degeneration in the brainstem and spinal cord, but also elicits skeletal muscle degeneration (1, 2). It is caused by CAG repeat expansion mutations in the AR gene, and usually affects males in adulthood. Testosterone, an AR ligand, facilitates nuclear translocation and intranuclear accumulation of mutant AR with expanded polyglutamine (polyQ) tract. This leads to transcriptional dysregulation, and subsequent defects in pivotal cellular functions, resulting in cell degeneration (3-7). Ligand-dependent nuclear accumulation of mutant AR has been implicated as a key contributor to motor neuron degeneration accounting for SBMA pathogenesis (8-10).
Though the formation of nuclear inclusions is not frequent in patients' muscle (11, 12) , pathogenetic roles of myopathy has also been considered pivotal, since histopathological myopathic changes and elevation of serum creatine kinase levels, indicative of muscle degeneration, are among important SBMA signs (13). Muscle defects would fall short of providing trophic support for innervating motor neurons, which could cause non-cell autonomous neurodegeneration (14, 15) . In line with this view, muscle-specific overexpression of trophic factor IGF-1 ameliorates pathologies in an SBMA mouse model expressing human mutant AR with 97 glutamines (AR-97Q) (16), whereas muscle-restricted expression of rat AR induces motor neuron damage in mice (16, 17) . Also, a recent report described that genetic inactivation of mutant AR in muscle rescued a bacterial artificial chromosome (BAC) transgenic mouse carrying AR-121Q (BAC fxAR121 mouse) (18) . Supporting this finding, systemically administered antisense oligonucleotides (ASOs) that silenced mutant AR by guest on November 8, 2016 http://hmg.oxfordjournals.org/ Downloaded from 4 in muscles and peripheral tissues ameliorated behavioral and pathological phenotype of BAC fxAR121 and another knock-in model with AR-113Q (AR113Q mouse), whereas intracerebroventricular (ICV) administration of ASOs silencing mutant AR in the CNS had no beneficial effect (19) . These observations suggest a pivotal role of muscular mutant AR in pathogenesis of SBMA.
However, it is argued that model-specific phenotype in BAC fxAR121/AR113Q mice such as marked myopathy might be associated with the observed results in this ASO study (19) . Given that profound nuclear inclusions in motor neurons and extensive neuronal loss are the fundamental human SBMA pathology, inherently vulnerability of motor neurons should also be taken into account (10, 20) . Neurogenic contraction fasciculation in muscle is one of the initial symptoms of SBMA, and neurogenic abnormalities in electromyogram are evident even in affected male subjects as well as in asymptomatic female carriers (10, 21) . Additionally, sensory and autonomic neuropathies are involved in SBMA patients (22) (23) (24) (25) . Thus the relative importance between motor neuron and muscle lesion in SBMA still remains inconclusive (19) .
In our transgenic AR-97Q mouse, SBMA-like neuropathology in motor neurons and neuromuscular junctions is well characterized (26, 27) . This further prompted us to address neuropathogenesis in SBMA and explore therapeutic effects of antisense knockdown of mutant AR in the CNS including motor neurons of this model. We demonstrate that ICV ASO injection, suppressing spinal mutant AR levels, ameliorated disease phenotypes of AR-97Q mice including motor dysfunction and neuronal histopathology without overt adverse effects. This effect is achieved through its potential effects against neurotoxicity of mutant AR. This effect was also observed even with concomitant suppression of endogenous Ar in the CNS without altering circulating testosterone levels. Besides myopathic defects, CNS pathology in SBMA by guest on November 8, 2016
http://hmg.oxfordjournals.org/ Downloaded from contributes to the pathogenesis and can also be a therapeutic target with lowering mutant AR by ASOs.
Results

ASO inhibits mutant AR expression in the SBMA mouse CNS
AR-97Q male mice demonstrate SBMA-like progressive motor dysfunction beginning as early as 8 weeks old with characteristic nuclear accumulation of mutant AR especially in the spinal motor neurons and muscles, and die with a median survival of 13-15 weeks. Females manifest only limited phenotype, recapitulating gender-related differences in human (26). We developed cEt/2′-MOE or 2′-MOE gapmer ASOs, which triggers RNase H cleavage and thus RNA degradation, complementary to both human AR and mouse Ar transcripts or only to human AR transcript (ASO-AR1 or ASO-AR2, respectively) (Supplementary Material, Table S1 ) (19) . Since the blood-brain barrier in mature mice blocks the access of peripherally administered cEt/MOE ASOs to the CNS (28), we used ICV administration to directly distribute ASOs throughout the CNS under cerebrospinal fluid flow. We administered 2.0-6.0 mg/kg body weight of ASO-AR1, 4.0 mg/kg of ASO-AR2 or saline control as a single ICV injection, in 5-week-old males. The ASO effect on AR expression in the spinal cord was analyzed at 7 weeks old, 2 weeks after treatment. Semi-quantitative radioactive RT-PCR revealed that 4.0 mg/kg ASO-AR1 gave 50% and 90% decreases in mutant AR and mouse Ar, respectively, and ASO-AR2 suppressed mutant AR only (Fig. 1A) . There was a dose-dependent trend of ASO-AR1 knockdown of mutant AR, and there was a sustained effect at least until 10 weeks old, shown by a time-course study (Fig. 1A) . Immunoblot analysis revealed a corresponding reduction in mutant AR levels by ASO-AR1 (Fig. 1B) . ASO-AR1 had a similar knockdown effect in brain 6 but no effect in muscle and liver, consistent with patterns of the ASO-parenchymal uptake (Fig. 1C, 1D , 3B, Supplementary Material, Fig. S1A and S3 ), as shown previously (19, (28) (29) (30) .
ASO ameliorates clinical phenotypes in the SBMA mice
We observed beneficial effects of both ASOs on disease onset and progression. The 4.0 mg/kg of both ASOs successfully extended the life span, retained motor function measured with serial grip and rotarod-task tests, as well as body weight gain ( Fig. 2A-D) . A previous report demonstrated that prenatal loss of endogenous Ar enhances motor neuronal pathology through increased testosterone levels in SBMA mice (31).
Though ASO-AR1 simultaneously suppresses endogenous Ar, in addition to human mutant AR, serum testosterone levels were maintained at the normal levels in the treated mice (Fig. 2E) . Also, ASO-AR1 did not affect motor function, weight gain or survival in wild-type C57BL/6J mice under similar inhibition of mouse Ar in the spinal cord, indicating tolerability of this ASO strategy (Supplementary Material, Fig. S1B and S2) . In contrast, 6.0 mg/kg of ASO-AR1 was less beneficial for survival ( Fig.   2A ), which could be potentially due to toxic effect of high-dose ASO (see below) (28, 32). However, cEt/MOE ASOs minimizes inflammation, in accordance with no marked increase in Aif1 mRNA expression, a macrophage/microglia activation marker (33), in the spinal cord (Supplementary Material, Fig. S1C ) (29, 34) .
ASO ameliorates histological phenotypes in the SBMA mice
Motor neuron pathology
Nuclear accumulation of mutant AR is the pathological hallmark of SBMA (10, 12).
In ASO-AR1-treated mice, immunohistochemical (IHC) analysis with anti-polyQ 7 antibody 1C2 showed a decrease in the frequency of -motor neurons with nuclear mutant AR accumulation at 13 weeks old (Fig. 3A) . IHC showed predominant ASO uptake/distribution in the CNS including spinal motor neurons, while almost no cellular uptake in the peripheral tissues such as muscle and heart, though we detected exceptional ASOs in liver sinusoids and renal tubules ( 
Muscle pathology
We next assessed the ASO effect on muscular defects, one of the key pathologies of SBMA. The number of myocyte with 1C2-positive nuclear accumulation of mutant AR was not substantially decreased by ASO-AR1, which was hardly uptaken in skeletal muscle (Fig. 4A, Supplementary Material, . Nevertheless, H&E staining showed the retained myofiber sizes in ASO-AR1-treated mice, contrasting with the smaller myofiber sizes and atrophic fibers seen in control mice at 8 denervation (35) , were evident in control mice, but markedly decreased by ASO-AR1 (Fig. 4C) . Furthermore, the expression of Myogenin (Myog), a marker of denervated muscle (36) , which is increased in SBMA mouse (19) and another motor neuron disease amyotrophic lateral sclerosis mouse (37, 38) , was suppressed in ASO-AR1-treated mice (Fig. 4D, E) .
Neuromuscular junction pathology
Structural defects in neuromuscular junctions (NMJs) such as fragmented endplates, denervation and increased synaptophysin staining were reported in SBMA mice (5, 27). AR-97Q mice display kyphosis, a sign of axial muscle defects, as seen in mouse models of motor neuron diseases such as ALS and spinal muscular atrophy (SMA).
We assessed NMJ structure in longissimus capitis (LC), axial muscle in the neck, in mice that were ICV-injected with 4.0 mg/kg ASO-AR1, at late-stage 15 weeks old.
Immunofluorescent NMJ staining showed that ASO-AR1 increased the number of mature pretzel forms of endplate acetylcholine receptor (AChR) and decreased the number of fragmented endplates, that are reported in aged, denervated or dystrophic muscles ( Fig. 5A) (30, 39) . Moreover, reduction of fully innervated NMJs (see the Materials and Methods) was significantly prevented (Fig. 5B) . In contrast, accumulation of synaptophysin staining, labeling for presynaptic terminals, was not apparent in AR-97Q mice (Fig. 5B) . Taken together, the present study demonstrated that, even with concomitant knockdown of endogenous Ar, ICV-administered ASO-AR1 had therapeutic effects on the pathology in the CNS including lower motor neurons and delayed its onset, resulting in subsequent amelioration of neurogenic disease phenotypes in the skeletal muscle and NMJs.
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ALS and SMA mice (34, 40, 41) . Further analysis of efficacy of the earlier and/or repeated ICV ASO administration may help to develop this strategy in SBMA mice.
We also observed the therapeutic effectiveness of ASO-AR2, which specifically hybridize only to human AR, in AR-97Q mice. This indicates that, the ASO potency, either abrogating endogenous Ar or not, is likely achieved through its mitigation of mutant AR-mediated neurotoxicity in the CNS, while mouse Ar-null background exacerbates disease phenotype by increasing testosterone levels due to androgen insensitivity (31). However, in contrast to the ubiquitous loss of endogenous Ar which begins embryonically, our approach was incomplete and temporary deprivation of Ar exclusively in the CNS at late postnatal stages. Our less potent approach retains circulating testosterone levels ( In contrast to our results, ICV injection of ASO-AR1, referred as ASO3, was reported ineffective to improve motor function and survival in a BAC fxAR121 mouse model (19) . These inconsistent results between the two studies might in part reflect the difference in the optimal dose and timing of the administration for each model, which may correlate with each overall prognosis. Another important difference between these mouse phenotypes is the involvement of distinct symptoms including urinary tract involvement in AR113Q or BAC fxAR121 mice (19) , whereas AR-97Q mice 
Materials and Methods
Oligonucleotides cEt/ 2′-MOE/DNA oligonucleotides with a phosphorothioate backbone and all 5-methylcytosines were synthesized and purified as described (19) . The sequences of ASOs we used are listed in Supplementary Material, Table S1 .
Animals and mouse physiology
Mouse protocols were in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals and were approved by Nagoya University Animal Experiment Committee. AR-97Q mice were generated, and the rotarod task and grip-strength test were carried out as described (26).
ICV injection
Five-week-old mice were anaesthetized with 40 mg/kg pentobarbital sodium and held by the head in a stereotaxic instrument. Five microliters of saline as control or 20 µg/µl of each ASO in saline was injected into the right lateral ventricle. The coordinates for injection were: 1 mm lateral from the sagittal suture, 0.2 mm posterior from the bregma and 3 mm deep from the brain surface. (1:5000, Sigma-Aldrich). One-ml blood was collected by cardiocentesis for an assay of serum testosterone levels using a radioimmunoassay (LSI Medience Corporation).
Mouse histology
Tissue sections for histopathological analysis were prepared and immunostained as described (6, 26, 47) . Flash-frozen quadriceps muscle was cut into 12-µm sections for (6), using an BZ-X700 microscope (Keyence).
For NMJ staining, after perfusing and post-fixing with 4% paraformaldehyde, longissimus capitis muscle was dissected and teased into layers five to 10 fibers thick. 
Statistical analysis
The data was analyzed using two-tailed t tests, and considered p values 0.05 to be statistically significant. Kaplan-Meier survival curves were prepared with Mantel-Cox tests using GraphPad Prism Software. 
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